Congratulations to Rich Liekweg, BJC Health System CEO, who announced his plans to retire on October 1, 2025.
BJC is pleased to announce that Nick Barto, current BJC Health System President, will succeed Rich as President and CEO of BJC Health System: https://t.co/Gr9YwBAIzu
Saint Luke’s Cancer Institute is featured in ACCC’s new video series on using genomics to expand access to clinical trials.
Watch the series from ACCC for more on how our team is advancing the future of cancer care: https://t.co/xyO7DokPOi
Saint Luke's Cancer Institute's new Comprehensive Cancer Program is now open on the campus of Saint Luke's North Hospital-Barry Road! 🎉
Take an inside look with Dan and Dr. Zach Nicholas, Director of Radiation Oncology, to see all this expanded space has to offer.
#ASCO25 Day 2: so proud of our two stellar residents, soon to be fellows! @Meddoc77 (Himil Mahadevia) and Parth Sharma. Congrats on the posters, can’t wait to see what your futures hold! @SLCI_KC@saintlukeskc
Happy to work in a practice with great people that enjoy blowing off some steam at the end of the week. Cheers to many more happy hours! @saintlukeskc@SLCI_KC
Calling all thoracic oncologists - Saint Luke’s in Kansas City is hiring! We have robust precision and research programs. DM me to get more information on how to join the wonderful folks in our practice! https://t.co/18KXBkYLNa @saintlukeskc
Join us alongside gastrointestinal medical oncologist @MarcRothMD of @StLukesSTL April 25 at 1pm EST for a deep dive into biomarker testing and how it fits into your care plan!
Register today!
https://t.co/oYApRMGGIO
We’re excited to announce the recent opening of PRISM-1 via @arcusbio, a P3 trial for pts with met pancreatic cancer! Trial is exploring gem/abraxane +/- quemliclustat. Oncology needs panc trials! 👏 👏👏@saintlukeskc
https://t.co/p2vpTibNQf
Our correspondence is now available on @TheLancet!
Differences in HCC etiology may contribute to the positive result of camrelizumab plus rivoceranib in CARES-310 trial, in contrast to other IO+TKI trials. Thank you @MarcRothMD@SLCI_KC for the support.
https://t.co/S1MkcfiOrR
More than happy to have a review on predictive biomarkers for irAE.
Prospective studies that capture irAE proactively better and incorporating scoring system to predict irAE are the future directions.@dhruvsxu @RamSubraMD@Khan7013@SLCI_KC@Cancers_MDPI
https://t.co/oxfzPOoGrH
The day we’ve been waiting for! @US_FDA approves fruquitinib for refractory met #colorectal#cancer providing another option for our patients! Thank you to mentor @CathyEngMD and others on this tremendous effort! @SLCI_KC@saintlukeskc
https://t.co/KIZwvMAvOX
Check out our new case report on a patient w #colorectal#cancer and a T790M mutation who responded to targeted therapy w osimertinib. Collab between @SLCI_KC Center for Precision Oncology and @UMKC. https://t.co/E5GjDBpFgy @dhruvsxu @JBuckleyMD @saintlukeskc#teamsaintlukes
📢 New provider spotlight: We're excited to welcome Norin Ansari MD MPH to Saint Luke's Cancer Institute! She comes from @YaleCancer@YaleHemOnc fellowship and is happy to back home in the Midwest. Dr. Ansari is seeing new patients at @SLCI_KC East in Lee's Summit, MO. Welcome!🤗
St Luke's precision oncology program reports improved outcomes for patients with @saintlukeskc molecular tumor board-directed therapy at the ESMO conference in Madrid
@SLCI_KC and #WCLC2023 !
@dhruvsxu Dr. Bansal presents interesting findings, delving deep into the cancer transcriptome to find subsets of individuals with cancer who might benefit from checkpoint inhibitor therapy.